Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.55 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | GRK2 | P25098 | 2/20 | 0.50 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272757 | 1.00 | AKT1 (0.55) | AKT1AKT2DYRK1ACLK4PDE4B | |
| Hydrochloric Acid SCHEMBL25272153 | 0.98 | AKT1 (0.53) | AKT1AKT2DYRK1ACLK4PDE4B | |
| SCHEMBL27630914 | 0.88 | ROCK2 (0.47) | AKT1AKT2PDE4BROCK2ROCK1 | |
| SCHEMBL25424764 | 0.83 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL30245585 | 0.83 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL30424015 | 0.82 | AKT2 (0.71) | AKT1AKT2DYRK1ACLK4ROCK2 | |
| SCHEMBL196765 | 0.80 | CYP3A4 (0.73) | DYRK1ACLK4CYP1A1CYP1A2CYP2E1 | |
| SCHEMBL29489425 | 0.80 | CYP3A4 (0.73) | DYRK1ACLK4CYP1A1CYP1A2CYP2E1 | |
| SCHEMBL13737920 | 0.79 | LMNA (0.50) | AKT1AKT2ROCK2ROCK1CYP3A4 | |
| SCHEMBL31194828 | 0.78 | AKT1 (0.50) | AKT1AKT2ROCK2ROCK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | AKT1 4454/4885AKT2 3690/4885DYRK1A 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.